Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028?
Health & MedicineOne-Off2a
Manifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoPrevisione della comunità attuale
No 66.2%
Previsori
4
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 11 ore fa
Obsoleto16 ago 24, 00:43 UTC1 gen 29, 07:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
Will Lantern Bioworks Lumina treatment be FDA Approved for preventing tooth decay by the end of 2028?
Manifold MarketsWill there be an FDA Approved treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by 2030.
Manifold MarketsWill Retatrutide (new obesity drug) be FDA approved by the end of 2026?
Manifold MarketsOrion (a device that promises to project artificial vision into the brains of blind people) approved for sale by the end of 2027?
FutuurRaniPill microneedle pill to replace injections: approved for sale by the end of 2026?
FutuurTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurRegole
Glioblastoma (GBM) is a malignant brain tumor which has an overall survival average of >2 years.
- Current FDA approved treatments which positively impact survival include surgical resection, temozolomide chemotherapy, radiation, and tumor treating fields (TTF).
- The most recent approval which would qualify was a TTF device called Optune, which was approved in 2015.
- For this market to resolve YES, the drug(s) or device must be novel — drug repurposing doesn’t count unless the delivery system is truly novel.
- Surgical and radiological advancements generally will not count: however, surgically implantable devices which are novel and confer a survival benefit do count.
- Market will resolve YES even if the novel treatment is only approved to treat a subset of GBM patients.
Mercati aperti
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume totale
- 15,6 Mln €
- Volume 24h
- 18,3K €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume totale
- 1,6 Mln €
- Volume 24h
- 5,2K €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 altri esiti
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume totale
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume totale
- 916K €
- Volume 24h
- 1,5K €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 altri esiti
- Volume totale
- 863,6K €
- Volume 24h
- 1K €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Domande frequenti
- Quali sono le probabilità attuali per Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028??
- Manifold Markets quota No al 66% al 8 settembre 2026.
- Quando si risolve Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028??
- Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028? dovrebbe risolversi il 1 gennaio 2029.
- Come viene liquidato Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028??
- Manifold Markets liquida questo mercato come segue: Glioblastoma (GBM) is a malignant brain tumor which has an overall survival average of >2 years.